SB-258719 is a drug developed by GlaxoSmithKline which acts as a selective 5-HT7 receptor partial inverse agonist,[1] and was the first such ligand identified for 5-HT7.[2] Its use in research has mainly been in demonstrating the potential use for 5-HT7 agonists as potential novel analgesics, due to the ability of SB-258719 to block the analgesic effects of a variety of 5-HT7 agonists across several different testing models.[3][4][5][6]
Identifiers | |
---|---|
| |
CAS Number |
|
PubChem CID |
|
IUPHAR/BPS |
|
ChemSpider |
|
ChEMBL |
|
Chemical and physical data | |
Formula | C18H30N2O2S |
Molar mass | 338.51 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(what is this?) (verify) |